Hello manoj kumar valluru,
Last week a population of Oct4A positive stem cell-like cells were described in healthy and cancers prostates. The more undifferentiated the prostate cancer cells were, the higher number of these cells were present. This was interesting since these cells did not express "conventional" cancer stem cell markers such as CD133 and the drug efflux pump.
A patent #7,459,541 was issued on fusion proteins that specifically bind damaged tissue. These are fusions between a specific domain of vWF and various growth factors already in clinical use. This is an interesting one to look into for commercialization.
Another patent of interest, #7,459,152, was issued covering the use of erythropoietin to augment stem cell/neural transplants for treatment of Parkinson's.
Note: Next week's newsletter will be delivered on Tuesday.
|
|
The 3rd Annual Stem Cells World Congress (20-22 January 2009)
The Stem Cell Meeting (March 2009)
|
|
Thanks again for your help in supporting StemCellPatents.com.
We welcome your comments and suggestions! Tell us here.
Media Partnerships (NEW)